Amylyx Pharmaceuticals (AMLX) Change in Interest Receivables (2021 - 2025)
Amylyx Pharmaceuticals' (AMLX) quarterly Change in Interest Receivables came in at -$6000.0 in Q4 2025, up 89.29% year-on-year from -$3169.8 in Q4 2024, and down 110.91% quarter-over-quarter from $55000.0 in Q3 2025.
Amylyx Pharmaceuticals (AMLX) Change in Interest Receivables (2021 - 2025) Analysis & Trends
Amylyx Pharmaceuticals' Change in Interest Receivables history runs 5 years deep, the most recent figure standing at -$6000.0 for Q4 2025.
- On a quarterly basis, Change in Interest Receivables rose 89.29% year-over-year to -$6000.0 in Q4 2025; TTM through Dec 2025 was -$24000.0, a 93.31% increase from a year earlier, with the FY2025 full-year figure at -$24000.0, up 93.31% from the prior year.
- Change in Interest Receivables declined to -$6000.0 in Q4 2025 per AMLX's latest filing, from $55000.0 in the prior quarter.
- Across five years, Change in Interest Receivables topped out at $609000.0 in Q2 2023 and bottomed at -$726000.0 in Q3 2023.
- The 5-year median for Change in Interest Receivables is -$6000.0 (2025), against an average of -$52411.8.
- Biggest YoY gain for Change in Interest Receivables was 4975.0% in 2023; the steepest drop was 25400.0% in 2023.
- Year by year, Change in Interest Receivables stood at $2000.0 in 2021, then tumbled by 27500.0% to -$548000.0 in 2022, then soared by 163.32% to $347000.0 in 2023, then sank by 116.14% to -$56000.0 in 2024, then soared by 89.29% to -$6000.0 in 2025.
- Per Business Quant, the three latest AMLX Change in Interest Receivables figures stand at -$6000.0 (Q4 2025), $55000.0 (Q3 2025), and -$7000.0 (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Interest Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Amylyx Pharmaceuticals | 1.94 Bn | 1.94 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -6,000.00 |
| Sep 30, 2025 | 55,000.00 |
| Jun 30, 2025 | -7,000.00 |
| Mar 31, 2025 | -66,000.00 |
| Dec 31, 2024 | -56,000.00 |
| Sep 30, 2024 | 118,000.00 |
| Jun 30, 2024 | -304,000.00 |
| Mar 31, 2024 | -117,000.00 |
| Dec 31, 2023 | 347,000.00 |
| Sep 30, 2023 | -726,000.00 |
| Jun 30, 2023 | 609,000.00 |
| Mar 31, 2023 | -253,000.00 |
| Dec 31, 2022 | -548,000.00 |
| Sep 30, 2022 | 48,000.00 |
| Jun 30, 2022 | 12,000.00 |
| Mar 31, 2022 | 1,000.00 |
| Mar 31, 2021 | 2,000.00 |